MasterControl has added three new cloud-based analytical solutions to its MasterControl Version 11.7 software for clinical managers and regulatory/submissions professionals.
MasterControl, a provider of integrated software solutions, added three new cloud-based analytical solutions to its MasterControl Version 11.7 software. The eTMF Manager is a software system that automates, centralizes, and standardizes the trial master file process for clinical studies. Registrations, a submission system for product registration and 510(k) device submission management, automates manual or hybrid processes, tracks various requirements globally, and creates transparency for the monitoring of submission bottlenecks. Registrations for eCTD is a publishing software for product registration and electronic common technical documents management. According to the company, these systems are suited to provide clinical managers, as well as regulatory and submissions professionals, the tools and methods needed to improve product time to market.
The updated version includes an analytic engine by JReport, a customizable reporting and business intelligence solution, and allows users to view, filter, and interact with their data more than previous versions of the software. Expanded capabilities include a stylized preview of reports in the form of icons, an interactive editor mode, and two user modes. The editor mode enables users to change column size, add or remove columns, create new data columns for statistics such as percentages and column math, and create new data within the report. Additionally, users can add or subtract columns, images, groupings, summary fields, calculated fields, filters, labels, and graphics.
Source: MasterControl
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
August 5th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.